Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04504331 · ClinicalTrials.gov registry record · Phase 1
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
A Phase 1 study, sponsored by Jennifer Lee Caswell-Jin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04504331: Clinical Trial Phase 1 study, sponsored by Jennifer Lee Caswell-Jin.
NCT04504331 is a Phase 1 study that was terminated before completion, run by Jennifer Lee Caswell-Jin. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04504331, a Phase 1 study, was terminated before completion, sponsored by Jennifer Lee Caswell-Jin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
Interventions
- DRUG Tamoxifen
- DIAGNOSTIC_TEST Computed tomography (CT)
- DRUG Iopamidol
- DRUG Infigratinib
- DRUG Omnipaque 350
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2021-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04504331
The ClinicalTrials.gov registry entry for NCT04504331 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jennifer Lee Caswell-Jin, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tamoxifen is the first listed.
NCT04504331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04504331 about?
NCT04504331 is a clinical study titled "Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer". The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
What is the current status of trial NCT04504331?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-10-13. Estimated completion is 2021-10-22.
What interventions are being tested in trial NCT04504331?
The interventions under investigation include: Tamoxifen (DRUG), Computed tomography (CT) (DIAGNOSTIC_TEST), Iopamidol (DRUG), Infigratinib (DRUG), Omnipaque 350 (DRUG).
Who is sponsoring clinical trial NCT04504331?
This trial is sponsored by Jennifer Lee Caswell-Jin, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.